<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117464</article-id><article-id pub-id-type="publisher-id">ACM-44143</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_51006215.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  β肾上腺受体阻滞剂在肿瘤治疗中的研究进展
  Progress in Studies of β Adrenal Receptor Blockers in Tumor Therapy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>锦琼</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>丽娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>永萍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>大理大学第一附属医院，云南 大理</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3196</fpage><lpage>3202</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  β肾上腺受体是儿茶酚胺类物质，主要包括β1-AR、β2-AR、β3-AR，临床上主要用于心血管方面疾病。现研究发现其表达于多种肿瘤细胞，对肿瘤细胞增殖、迁移、侵犯等具有促进作用，可利用β受体阻滞剂进行抗肿瘤靶向或协同治疗抑制肿瘤细胞生物学行为，为肿瘤治疗带来新的方向和希望。
   Beta-adrenergic receptors are catecholamines, mainly including β1-AR, β2-AR, and β3-AR, and are clinically used mainly for cardiovascular diseases. The present study found that it is expressed in a variety of tumor cells, and has a promoting effect on tumor cell proliferation, migration, invasion, etc., can use β-blockers for anti-tumor targeting or synergistic therapy to inhibit the biological behavior of tumor cells, bringing new directions and hopes for cancer treatment.
 
</p></abstract><kwd-group><kwd>肿瘤，β肾上腺素受体，β受体阻滞剂, Tumor</kwd><kwd> β-Adrenergic Receptor</kwd><kwd> β-Receptor Blocker</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>β肾上腺受体是儿茶酚胺类物质，主要包括β1-AR、β2-AR、β3-AR，临床上主要用于心血管方面疾病。现研究发现其表达于多种肿瘤细胞，对肿瘤细胞增殖、迁移、侵犯等具有促进作用，可利用β受体阻滞剂进行抗肿瘤靶向或协同治疗抑制肿瘤细胞生物学行为，为肿瘤治疗带来新的方向和希望。</p></sec><sec id="s2"><title>关键词</title><p>肿瘤，β肾上腺素受体，β受体阻滞剂</p></sec><sec id="s3"><title>Progress in Studies of β Adrenal Receptor Blockers in Tumor Therapy<sup> </sup></title><p>Jinqiong Li, Lijuan He, Yongping Li</p><p>The First Affiliated Hospital of Dali University, Dali Yunnan</p><p><img src="//html.hanspub.org/file/45-1572395x4_hanspub.png?20210727090245022" /></p><p>Received: Jun. 21<sup>st</sup>, 2021; accepted: Jul. 11<sup>th</sup>, 2021; published: Jul. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/45-1572395x5_hanspub.png?20210727090245022" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Beta-adrenergic receptors are catecholamines, mainly including β1-AR, β2-AR, and β3-AR, and are clinically used mainly for cardiovascular diseases. The present study found that it is expressed in a variety of tumor cells, and has a promoting effect on tumor cell proliferation, migration, invasion, etc., can use β-blockers for anti-tumor targeting or synergistic therapy to inhibit the biological behavior of tumor cells, bringing new directions and hopes for cancer treatment.</p><p>Keywords:Tumor, β-Adrenergic Receptor, β-Receptor Blocker</p><disp-formula id="hanspub.44143-formula21"><graphic xlink:href="//html.hanspub.org/file/45-1572395x6_hanspub.png?20210727090245022"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/45-1572395x7_hanspub.png?20210727090245022" /> <img src="//html.hanspub.org/file/45-1572395x8_hanspub.png?20210727090245022" /></p></sec><sec id="s5"><title>1. 引言</title><p>β肾上腺素受体阻断剂(Beta blockers)，是一类在临床上用来治疗心律不齐、冠心病二级预防和在某些情况下用来治疗高血压的药物。在心血管系统疾病中广泛应用，β肾上腺素受体阻断药非竞争性阻断交感神经系统中内源性儿茶酚胺肾上腺素和去甲肾上腺素的作用，尤其是肾上腺素β受体。有些药物阻断所有β-肾上腺素能受体，有些则为竞争性阻断 [<xref ref-type="bibr" rid="hanspub.44143-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44143-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.44143-ref3">3</xref>]。目前β肾上腺素受体阻滞剂在临床中应用种类较多，主要应用有美托洛尔、普萘洛尔、阿替洛尔、噻吗洛尔等。</p><p>儿茶酚胺是影响肿瘤进展的主要因素。它可以通过由癌细胞表达的肾上腺素能受体(ADR)来调节多种细胞信号传导途径。激活的ADR增强癌细胞的增殖和侵袭能力，改变肿瘤微环境中的细胞活性，调节癌症与其微环境之间的相互作用以促进肿瘤进展。儿茶酚胺类物质对肿瘤细胞的增殖和凋亡具有促进作用，对血管生成、肿瘤细胞转移和肿瘤相关的免疫应答也具有促进能力 [<xref ref-type="bibr" rid="hanspub.44143-ref4">4</xref>]，β受体目前在肿瘤细胞表达成为近年研究热点，但其确切的机制尚未清楚，有待于进一步研究，结合其肿瘤细胞表面表达的特点，为β受体阻滞剂在临床上抗恶性肿瘤治疗提供新的思路和方向。确切机制需进一步探讨和研究，目前就β受体阻滞剂治疗恶性肿瘤做综述。</p></sec><sec id="s6"><title>2. β肾上腺素受体分类及作用机制</title><p>儿茶酚胺类物质主要包括α受体和β受体，目前已知β受体主要用β1受体、β2受体、β3受体。β1和β3主要分布在心肌细胞上，β1受体激动后可对心肌产生正性作用，导致心肌兴奋产生一系列反应，如：收缩加剧、心脏射血速度加快、心率上升等，阻断剂：普萘洛尔、阿替洛尔；β3受体激动后可产生负性肌力作用，可能参与了心衰的病理生理过程。目前认为β3受体通过抑制性G蛋白引起负性变力效应，也可能是通过一氧化氮途径介导。目前在肿瘤细胞中应用较多的是β2肾上受体，它分布在支气管平滑肌、血管平滑肌以及心肌等分布，作用为介导支气管平滑肌的松弛、扩张血管。β肾上腺素受体可通过与GS蛋白结合，激活腺苷酸环化酶(AC)，使三磷酸腺苷(ATP)向环磷酸腺苷(CAMP)转化，引起细胞内CAMP水平升高，CAMP激活PKA途径，从而发挥生物学效应。</p></sec><sec id="s7"><title>3. β肾上腺素受体阻滞剂在肿瘤中的研究进展</title><sec id="s7_1"><title>3.1. 血管瘤</title><p>普萘洛尔作为β-肾上腺素能受体(AR)的非选择性阻断剂，MARIA 等医生使用普萘洛尔眼周婴儿血管瘤，9名眼周婴儿血管瘤患儿接受普萘洛尔，治疗后发现血管瘤颜色衰减和体积缩小 [<xref ref-type="bibr" rid="hanspub.44143-ref5">5</xref>]。利用小鼠异种移植血管瘤模型中，显示普萘洛尔主要通过作用于β2-AR，以剂量和时间依赖的方式降低血管瘤细胞中HIF-1α的表达。观察到HIF-1α的过度表达明显地消除了普萘洛尔对血管内皮生长因子(VEGF)表达和细胞生长的抑制作用。普萘洛尔抑制信号转导和转录激活因子3 (STAT3)和抗凋亡蛋白Bcl-2。此外，HIF-1α的过度表达逆转普萘洛尔对STAT3信号传导的抑制作用。HIF-1α的过度表达显著减弱普萘洛尔的治疗效果，并抑制普萘洛尔诱导的血管瘤细胞凋亡。表明普萘洛尔可以通过以HIF-1α依赖性方式抑制VEGF和STAT3信号传导途径而使婴儿血管瘤退化 [<xref ref-type="bibr" rid="hanspub.44143-ref6">6</xref>]。血管瘤消退机制主要是普萘洛尔阻断血管瘤表面的β1受体和β2受体，促进β2受体与Gi藕连，通过BCL-2/BAX和FAS/Fas配体两条信号通路，激活capase-3，促进肿瘤细胞凋亡；另外通过协同抑制β1受体与Gs的藕连，通过G蛋白/AC/cAMP/PKA信号通路对ERK/MAPK信号通路的激活，抑制VEGF的分泌，引起血管瘤的缩小 [<xref ref-type="bibr" rid="hanspub.44143-ref7">7</xref>]。</p></sec><sec id="s7_2"><title>3.2. 结直肠癌</title><p>已经显示应激上调的儿茶酚胺激活的β1-和β2-肾上腺素能受体(β1/2-AR)可加速癌症例如结直肠癌(CRC)的进展 [<xref ref-type="bibr" rid="hanspub.44143-ref8">8</xref>]。众所周知，β体是G蛋白偶联受体，它们的激活会引起复杂的细胞内信号转导参与肿瘤的发生发展过程，如花生四烯酸级联的激活和其他途径，通过第二信使的环磷酸腺苷(cAMP) [<xref ref-type="bibr" rid="hanspub.44143-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.44143-ref10">10</xref>]。β2-AR拮抗作用通过抑制β2-AR反式激活的EFGR-Akt/ERK1/2信号通路选择性地抑制伴随活性β2-AR信号传导的直肠癌的生长 [<xref ref-type="bibr" rid="hanspub.44143-ref11">11</xref>]。使用普萘洛尔可抑制SW 480结肠癌细胞的增殖和迁移 [<xref ref-type="bibr" rid="hanspub.44143-ref12">12</xref>]。</p></sec><sec id="s7_3"><title>3.3. 胃癌</title><p>β2-AR激动剂异丙肾上腺素上调胃癌细胞中CD44和CD44v8-10的表达水平。癌症干细胞相关标志物CD44在胃癌组织中高水平表达，与体内和体外上皮–间质转化(EMT)相关表型的发生密切相关。结合人胃癌细胞系的实验观察，我们发现β2-AR信号可以启动EMT [<xref ref-type="bibr" rid="hanspub.44143-ref13">13</xref>]。在mRNA和蛋白质水平上导致间充质标志物如α-SMA，波形蛋白和蜗牛的表达增加，相反，上皮标志物E-钙粘蛋白和β-连环蛋白的表达减少。异丙肾上腺素刺激β2-AR受体激活下游靶点STAT3，其作为正调节剂并介导胃癌细胞中向间充质细胞类型的表型转换。我们的数据提供了机制的理解复杂的信号级联涉及压力相关激素及其对EMT的影响。根据我们的观察，针对β2-AR-STAT3信号传导的药理学干预可能潜在地用于改善与胃癌发展和进展相关的应激影响 [<xref ref-type="bibr" rid="hanspub.44143-ref14">14</xref>]。</p></sec><sec id="s7_4"><title>3.4. 乳腺癌</title><p>杨国清等使用免疫组化方法检测33例乳腺癌患者乳腺癌组织和10例正常乳腺组织β2-AR，实验结果两组之间具有显著差异性，证实乳腺癌组织中β2-AR表达率高，与乳腺癌的发生具有紧密的关系 [<xref ref-type="bibr" rid="hanspub.44143-ref15">15</xref>]。</p><p>Lucia Gargiulo等人证实了MCF-7乳腺癌细胞表达β2-AR，使用异丙肾上腺素的β-肾上腺素能刺激诱导培养基中生长的乳房细胞的分化，以及体内小鼠乳腺上皮的分支。异丙肾上腺素显着增加小鼠乳腺和MCF-10A细胞中ERα、Ephrine-B1和成纤维细胞生长因子的表达。在低分化小鼠导管癌中，异丙肾上腺素也降低肿瘤生长并诱导肿瘤分化。这项研究强调儿茶酚胺通过β-AR活化似乎参与乳腺发育，诱导成熟的胆管形成。推测使用β受体阻滞剂能抑制乳腺癌细胞的增殖 [<xref ref-type="bibr" rid="hanspub.44143-ref16">16</xref>]。临床前资料已开始探讨β-肾上腺素受体与乳腺癌发生的机制性病理生理。使用MDA-MB-468人乳腺癌细胞进行的研究表明，在去甲肾上腺素的作用下，这些细胞对迁移有促进作用。对去甲肾上腺素本身有趋化作用，表明去甲肾上腺素对转移性的发展有直接作用 [<xref ref-type="bibr" rid="hanspub.44143-ref17">17</xref>]。在另一项涉及同一类型乳腺癌细胞的实验中，β2-肾上腺素能激活环磷酸腺苷(CAMP)途径，上调粘附受体，下调抑癌基因，进一步诱导转移性肿瘤细胞 [<xref ref-type="bibr" rid="hanspub.44143-ref18">18</xref>]。在乳腺癌细胞中，肾上腺素可保护癌细胞免受凋亡。激活β2-肾上腺素能受体，进一步介导G蛋白偶联受体和次级信使的激活，特别是cAMP，促凋亡蛋白bcl-2相关死亡启动子失活 [<xref ref-type="bibr" rid="hanspub.44143-ref19">19</xref>]。</p><p>体外实验 [<xref ref-type="bibr" rid="hanspub.44143-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.44143-ref21">21</xref>] 小鼠乳腺癌模型进行体内研究，发现交感神经系统是乳腺癌转移的一种新的神经调节因子，对原发性肿瘤的生长没有抑制作用。</p><p>W. Kurtis Childers等利用meta分析乳腺癌复发、乳腺癌死亡和全因死亡率的可用风险比(HR)，并使用随机效应荟萃分析进行汇总。共5项研究纳入乳腺癌复发Meta分析。总共有22,988名患者被纳入乳腺癌复发分析。sψrensen等人的研究 [<xref ref-type="bibr" rid="hanspub.44143-ref22">22</xref>] 贡献了81.5%名参与分析的患者。显著有利于使用β-阻滞剂减少乳腺癌复发。在报告死亡率的4项研究中，β受体阻滞剂对风险没有显着影响(HR, 1.02; 95%CI, 0.75~1.37)。这项系统评价和meta分析的结果表明，使用β受体阻滞剂显着降低乳腺癌女性乳腺癌死亡的风险 [<xref ref-type="bibr" rid="hanspub.44143-ref23">23</xref>]。</p></sec><sec id="s7_5"><title>3.5. 胰腺癌</title><p>薛晶 [<xref ref-type="bibr" rid="hanspub.44143-ref24">24</xref>] 等建立胰腺癌小鼠模型和使用免疫组化方法检测在胰腺癌β-AR，荷瘤应激组裸鼠血清肾上腺素浓度平均值，单纯荷瘤组裸鼠血清肾上腺素浓度平均值协，两组差异有显著性，胰腺癌组织中β-AR表达高于正常胰腺组织。这项研究说明β-AR发生发展以及淋巴结的定向转移过程中发挥重要作用。</p><p>有学者建立小鼠胰腺癌模型，研究了慢性听觉应激和抑制应激对肿瘤生长的影响。结果慢性应激荷瘤小鼠循环类固醇水平、肾上腺酪氨酸羟化酶增高、免疫应答水平明显降低、肿瘤中VEGF表达增多、微血管密度增加、MMP-9表达增加、β-儿茶酚胺促进肿瘤细胞增殖。使用β受体阻滞剂普萘洛尔可使肿瘤转移减少 [<xref ref-type="bibr" rid="hanspub.44143-ref25">25</xref>]。</p></sec><sec id="s7_6"><title>3.6. 前列腺癌、卵巢癌、肺癌、胶质瘤等</title><p>β-阻滞剂的有益作用已在包括卵巢癌、前列腺癌和肺癌在内的几种癌症中得到证实，减少了54%。与未服用β-阻滞剂的前列腺癌患者相比 [<xref ref-type="bibr" rid="hanspub.44143-ref26">26</xref>]。服用β-阻滞剂的前列腺癌患者的死亡率有所下降，服用β-阻滞剂并接受雄激素剥夺治疗的男性患者的死亡率下降，在前列腺癌裸鼠中，前列腺癌患者腰椎淋巴结转移的发生随着去甲肾上腺素的暴露而增加，且随着去甲肾上腺素浓度的增加而增加(p = 0.032) [<xref ref-type="bibr" rid="hanspub.44143-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.44143-ref28">28</xref>]。非小细胞肺癌患者与未服用β受体阻滞剂的患者相比，无远处转移生存率、无病生存率和整体生存率均有提高 [<xref ref-type="bibr" rid="hanspub.44143-ref29">29</xref>]。</p><p>有学者研究去甲肾上腺素对人U-251恶性胶质瘤细胞内GSH浓度的影响，谷胱甘肽(GSH)在保护细胞免受氧化损伤中起关键作用。由于神经元依靠从星形胶质细胞提供的GSH来维持最佳的细胞内GSH浓度，所以星形胶质细胞的GSH浓度对于邻近神经元抗氧化应激的存活是重要的。用去甲肾上腺素处理细胞24 h浓度依赖性地增加其细胞内GSH浓度 [<xref ref-type="bibr" rid="hanspub.44143-ref30">30</xref>]。</p></sec><sec id="s7_7"><title>3.7. 白血病、多发性骨髓瘤、淋巴瘤</title><p>Maher等研究者发现交感神经系统(SNS)促进了MLL-AF9 AML模型中的白血病骨髓浸润，肾上腺素能信号促进白血病发生由白血病骨髓基质细胞上表达的β2而非β3肾上腺素受体转导 [<xref ref-type="bibr" rid="hanspub.44143-ref31">31</xref>]。Donald等 [<xref ref-type="bibr" rid="hanspub.44143-ref32">32</xref>] 在一项体外研究实验中采用NALM-6急性淋巴细胞白血病模型，观察慢性应激对人B前细胞ALL小鼠模型肿瘤进展的影响，采用体内生物发光成像技术，在肿瘤细胞接种后3周内用荧光素酶标记的NALM-6细胞追踪骨髓定植和全身播散。这项研究显示慢性应激可以通过β-肾上腺素能信号传导途径加速人类前B ALL肿瘤负荷的进展，并且这种作用被β-肾上腺素能拮抗剂普萘洛尔所阻断。</p><p>李婷等使用噻吗洛尔药物可抑制RPMI 8226多发性骨髓瘤细胞株增殖，加快凋亡，其机制可能与上调Bax、Caspase-9表达，及抑制Bcl-2有关 [<xref ref-type="bibr" rid="hanspub.44143-ref33">33</xref>]。也有研究 [<xref ref-type="bibr" rid="hanspub.44143-ref34">34</xref>] 示多发性骨髓瘤细胞具有合儿茶酚胺的关键酶，可合成儿茶酚胺，肾上腺素受体等激活骨髓瘤细胞增殖，普萘洛尔可促进多发性骨髓瘤细胞凋亡。</p><p>在一项B细胞淋巴瘤的Eμ-myc小鼠模型实验研究者发现长期β肾上腺素受体高表达信号传导对淋巴瘤进展和抗肿瘤免疫力的影响，β-AR信号传导显着抑制抗原特异性CD8<sup>+</sup>T细胞的增殖，慢性β-AR信号传导对CD8<sup>+</sup>T细胞具有免疫抑制作用，降低了CD8<sup>+</sup>T细胞靶向免疫疗法的功效 [<xref ref-type="bibr" rid="hanspub.44143-ref35">35</xref>]。</p></sec></sec><sec id="s8"><title>4. β肾上腺素受体肿瘤细胞表达情况及主要作用机制</title><p>综上所述，β-AR在多种肿瘤细胞株中证实存在表达，如乳腺癌、胰腺癌、前列腺癌、胃癌、结直肠癌、黑色素瘤、血管瘤、宫颈癌和多发性骨髓瘤等中，β-AR的敏感性与相关组织有关系。</p><p>β-AR对肿瘤生物学行为 [<xref ref-type="bibr" rid="hanspub.44143-ref36">36</xref>] 主要有：(1) 促进肿瘤细胞增生；(2) 促进肿瘤细胞转移；(3) 诱导肿瘤细胞逃逸。</p></sec><sec id="s9"><title>5. 讨论</title><p>目前β受体阻滞剂在治疗肿瘤方面具体机制尚未确切，有待于进一步拷证，但结合体外实验，证实β受体在多种肿瘤细胞表达，可为将来肿瘤靶向治疗提供新的方向。结合上述β受体阻滞剂在肿瘤中的应用，β受体阻滞剂在阻止交感神经对肿瘤的增殖、转移、侵犯、血管增生等方面具有潜在的应用价值。</p></sec><sec id="s10"><title>文章引用</title><p>李锦琼,何丽娟,李永萍. β肾上腺受体阻滞剂在肿瘤治疗中的研究进展Progress in Studies of β Adrenal Receptor Blockers in Tumor Therapy[J]. 临床医学进展, 2021, 11(07): 3196-3202. https://doi.org/10.12677/ACM.2021.117464</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44143-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Freemantle, N., Cleland, J., Young, P., et al. (1999) Beta Blockade after Myocardial Infarction: Systematic Review and Meta Regression Analysis. BMJ (Clinical Research ed), 318, 1730-1737. &lt;br&gt;https://doi.org/10.1136/bmj.318.7200.1730</mixed-citation></ref><ref id="hanspub.44143-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Cruickshank, J.M. (2017) The Role of Beta-Blockers in the Treatment of Hypertension. Advances in Experimental Medicine and Biology, 956, 149-166. &lt;br&gt;https://doi.org/10.1007/5584_2016_36</mixed-citation></ref><ref id="hanspub.44143-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Lindholm, L.H., Carlberg, B., Samuelsson, O. (2005) Should Beta Blockers Remain First Choice in the Treatment of Primary Hypertension? A Meta-Analysis. The Lancet (London, England), 366, 1545-1553.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(05)67573-3</mixed-citation></ref><ref id="hanspub.44143-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Antoni, M.H., Lutgendorf, S.K., Cole, S.W., et al. (2006) The Influence of Bio-Behavioural Factors on Tumour Biology: Pathways and Mechanisms. Nature Reviews Cancer, 6, 240-248. &lt;br&gt;https://doi.org/10.1038/nrc1820</mixed-citation></ref><ref id="hanspub.44143-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ginguerra, M.A., Saito, O., Fernandes, J., et al. (2018) Clinical and Radiological Evaluation of Periocular Infantile Hemangioma Treated with Oral Propranolol: A Case Series. American Journal of Ophthalmology, 185, 48-55.  
&lt;br&gt;https://doi.org/10.1016/j.ajo.2017.10.021</mixed-citation></ref><ref id="hanspub.44143-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Li, P., Guo, Z., Gao, Y., et al. (2015) Propranolol Represses Infantile Hemangioma Cell Growth through the Beta2-Adrenergic Receptor in a HIF-1alpha-Dependent Manner. Oncology Reports, 33, 3099-3107.  
&lt;br&gt;https://doi.org/10.3892/or.2015.3911</mixed-citation></ref><ref id="hanspub.44143-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">刘超, 刘少华, 王丽丽, 等. β肾上腺素受体在婴幼儿血管瘤发病机制中作用的探讨[J]. 口腔医学, 2011, 31(7): 434-5.</mixed-citation></ref><ref id="hanspub.44143-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Yao, H., Duan, Z., Wang, M., et al. (2009) Adrenaline Induces Chemoresistance in HT-29 Colon Adenocarcinoma Cells. Cancer Genetics and Cytogenetics, 190, 81-87. &lt;br&gt;https://doi.org/10.1016/j.cancergencyto.2008.12.009</mixed-citation></ref><ref id="hanspub.44143-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Jobling, P., Pundavela, J., Oliveira, S.M., et al. (2015) Nerve-Cancer Cell Cross-Talk: A Novel Promoter of Tumor Progression. Cancer Research, 75, 1777-1781. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-14-3180</mixed-citation></ref><ref id="hanspub.44143-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, D., Ma, Q.Y., Hu, H.T., et al. (2010) beta2-Adrenergic Antagonists Suppress Pancreatic Cancer Cell Invasion by Inhibiting CREB, NFkappaB and AP-1. Cancer Biology &amp; Therapy, 10, 19-29.  
&lt;br&gt;https://doi.org/10.4161/cbt.10.1.11944</mixed-citation></ref><ref id="hanspub.44143-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chin, C.C., Li, J.M., Lee, K.F., et al. (2016) Selective beta2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis. Journal of Cellular Physiology, 231, 459-472. &lt;br&gt;https://doi.org/10.1002/jcp.25092</mixed-citation></ref><ref id="hanspub.44143-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Masur, K., Niggemann, B., Zanker, K.S., et al. (2001) Norepinephrine-Induced Migration of SW 480 Colon Carcinoma Cells Is Inhibited by Beta-Blockers. Cancer Research, 61, 2866-2869.</mixed-citation></ref><ref id="hanspub.44143-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Shan, T., Cui, X., Li, W., et al. (2014) Novel Regulatory Program for Norepinephrine-Induced Epithelial-Mesenchymal Transition in Gastric Adenocarcinoma Cell Lines. Cancer Science, 105, 847-856.  
&lt;br&gt;https://doi.org/10.1111/cas.12438</mixed-citation></ref><ref id="hanspub.44143-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lu, Y.J., Geng, Z.J., Sun, X.Y., et al. (2015) Isoprenaline Induces Epithelial-Mesenchymal Transition in Gastric Cancer Cells. Molecular and Cellular Biochemistry, 408, 1-13. &lt;br&gt;https://doi.org/10.1007/s11010-015-2477-0</mixed-citation></ref><ref id="hanspub.44143-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">杨国清. 乳腺癌中β2肾上腺素受体的表达及其与Her-2、K-ras基因的相关性研究[D]: [硕士学位论文]. 苏州: 苏州大学, 2014.</mixed-citation></ref><ref id="hanspub.44143-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Gargiulo, L., May, M., Rivero, E.M., et al. (2017) A Novel Effect of Beta-Adrenergic Receptor on Mammary Branching Morphogenesis and Its Possible Implications in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 22, 43-57. &lt;br&gt;https://doi.org/10.1007/s10911-017-9371-1</mixed-citation></ref><ref id="hanspub.44143-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Drell, T.L.T., Joseph, J., Lang, K., et al. (2003) Effects of Neurotransmitters on the Chemokinesis and Chemotaxis of MDA-MB-468 Human Breast Carcinoma Cells. Breast Cancer Research and Treatment, 80, 63-70.  
&lt;br&gt;https://doi.org/10.1023/A:1024491219366</mixed-citation></ref><ref id="hanspub.44143-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Draoui, A., Vandewalle, B., Hornez, L., et al. (1991) Beta-Adrenergic Receptors in Human Breast Cancer: Identification, Characterization and Correlation with Progesterone and Estradiol Receptors. Anticancer Research, 11, 677-680.</mixed-citation></ref><ref id="hanspub.44143-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Lang, K., Drell, T.L.T., Lindecke, A., et al. (2004) Induction of a Metastatogenic Tumor Cell Type by Neurotransmitters and Its Pharmacological Inhibition by Established Drugs. International Journal of Cancer, 112, 231-238.  
&lt;br&gt;https://doi.org/10.1002/ijc.20410</mixed-citation></ref><ref id="hanspub.44143-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Sastry, K.S., Karpova, Y., Prokopovich, S., et al. (2007) Epinephrine Protects Cancer Cells from Apoptosis via Activation of cAMP-Dependent Protein Kinase and BAD Phosphorylation. The Journal of Biological Chemistry, 282, 14094-14100. &lt;br&gt;https://doi.org/10.1074/jbc.M611370200</mixed-citation></ref><ref id="hanspub.44143-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Slotkin, T.A., Zhang, J., Dancel, R., et al. (2000) Beta-Adrenoceptor Signaling and Its Control of Cell Replication in MDA-MB-231 Human Breast Cancer Cells. Breast Cancer Research and Treatment, 60, 153-166.  
&lt;br&gt;https://doi.org/10.1023/A:1006338232150</mixed-citation></ref><ref id="hanspub.44143-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Sorensen, G.V., Ganz, P.A., Cole, S.W., et al. (2013) Use of Beta-Blockers, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Risk of Breast Cancer Recurrence: A Danish Nationwide Prospective Cohort Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 2265-2272.  
&lt;br&gt;https://doi.org/10.1200/JCO.2012.43.9190</mixed-citation></ref><ref id="hanspub.44143-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Childers, W.K., Hollenbeak, C.S. and Cheriyath, P. (2015) beta-Blockers Reduce Breast Cancer Recurrence and Breast Cancer Death: A Meta-Analysis. Clinical Breast Cancer, 15, 426-431. &lt;br&gt;https://doi.org/10.1016/j.clbc.2015.07.001</mixed-citation></ref><ref id="hanspub.44143-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">薛晶. 心理应激对胰腺癌浸润、转移的影响及β2肾上腺素受体的检测[D]: [硕士学位论文]. 青岛: 青岛大学, 2011.</mixed-citation></ref><ref id="hanspub.44143-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Partecke, L.I., Speerforck, S., Kading, A., et al. (2016) Chronic Stress Increases Experimental Pancreatic Cancer Growth, Reduces Survival and Can Be Antagonised by beta-Adrenergic Receptor Blockade. Pancreatology, 16, 423-433. &lt;br&gt;https://doi.org/10.1016/j.pan.2016.03.005</mixed-citation></ref><ref id="hanspub.44143-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Diaz, E.S., Karlan, B.Y., Li, A.J. (2012) Impact of Beta Blockers on Epithelial Ovarian Cancer Survival. Gynecologic Oncology, 127, 375-378. &lt;br&gt;https://doi.org/10.1016/j.ygyno.2012.07.102</mixed-citation></ref><ref id="hanspub.44143-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Grytli, H.H., Fagerland, M.W., Fossa, S.D., et al. (2013) Use of Beta-Blockers Is Associated with Prostate Cancer-Specific Survival in Prostate Cancer Patients on Androgen Deprivation Therapy. The Prostate, 73, 250-260.  
&lt;br&gt;https://doi.org/10.1002/pros.22564</mixed-citation></ref><ref id="hanspub.44143-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Palm, D., Lang, K., Niggemann, B., et al. (2006) The Norepinephrine-Driven Metastasis Development of PC-3 Human Prostate Cancer Cells in BALB/c Nude Mice Is Inhibited by β-Blockers. International Journal of Cancer, 118, 2744-2749. &lt;br&gt;https://doi.org/10.1002/ijc.21723</mixed-citation></ref><ref id="hanspub.44143-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H.M., Liao, Z.X., Komaki, R., et al. (2013) Improved Survival Outcomes with the Incidental Use of Beta-Blockers among Patients with Non-Small-Cell Lung Cancer Treated with Definitive Radiation Therapy. Annals of Oncology, 24, 1312. &lt;br&gt;https://doi.org/10.1093/annonc/mds616</mixed-citation></ref><ref id="hanspub.44143-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Yoshioka, Y., Kadoi, H., Yamamuro, A., et al. (2016) Noradrenaline Increases Intracellular Glutathione in Human Astrocytoma U-251 MG Cells by Inducing Glutamate-Cysteine Ligase Protein via β3-Adrenoceptor Stimulation. European Journal of Pharmacology, 772, 51-61. &lt;br&gt;https://doi.org/10.1016/j.ejphar.2015.12.041</mixed-citation></ref><ref id="hanspub.44143-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Hanoun, M., Zhang, D., Mizoguchi, T., et al. (2014) Acute Myelogenous Leukemia-Induced Sympathetic Neuropathy Promotes Malignancy in an Altered Hematopoietic Stem Cell Niche. Cell Stem Cell, 15, 365-375.  
&lt;br&gt;https://doi.org/10.1016/j.stem.2014.06.020</mixed-citation></ref><ref id="hanspub.44143-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Lamkin, D.M., Sloan, E.K., Patel, A.J., et al. (2012) Chronic Stress Enhances Progression of Acute Lymphoblastic Leukemia via β-Adrenergic Signaling. Brain Behavior &amp; Immunity, 26, 635-641.  
&lt;br&gt;https://doi.org/10.1016/j.bbi.2012.01.013</mixed-citation></ref><ref id="hanspub.44143-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">李婷, 郭鹏翔, 雷霆雯, 等. 噻吗洛尔对人多发性骨髓瘤细胞株 RPMI 8226增殖、凋亡的影响及其机制[J]. 山东医药, 2016, 56(27): 24-27.</mixed-citation></ref><ref id="hanspub.44143-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">刘扬. β肾上腺素能受体通路对多发性骨髓瘤细胞的体外作用研究[D]: [博士学位论文]. 北京: 北京协和医学院, 2014.</mixed-citation></ref><ref id="hanspub.44143-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Nissen, M.D., Sloan, E.K. and Mattarollo, S.R. (2017) Beta-Adrenergic Signaling Impairs Anti-Tumor CD8+ T Cell Responses to B Cell Lymphoma Immunotherapy. Cancer Immunology Research, 6, 98-109.  
&lt;br&gt;https://doi.org/10.1158/2326-6066.CIR-17-0401</mixed-citation></ref><ref id="hanspub.44143-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">李婷, 郭鹏翔, 王季石. β肾上腺素能受体在肿瘤中的研究进展[J]. 医学综述, 2016, 22(13): 2557-2560.</mixed-citation></ref></ref-list></back></article>